𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response

✍ Scribed by Dung T. Le; Brian H. Ladle; Timothy Lee; Vivian Weiss; Xiaosai Yao; Ashley Leubner; Todd D. Armstrong; Elizabeth M. Jaffee


Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
674 KB
Volume
129
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The composition of tumor infiltrating lymphocytes (TIL) is heterogeneous. In addition, the ratio of various subpopulations in the tumor microenvironment is highly dependent on the nature of the host's immune response. Here, we characterize Foxp3‐expressing CD8^+^ T cells in the tumor that demonstrate effector function and accumulate in the context of an effective anti‐tumor response. CD8^+^Foxp3^+^ T cells are induced in TIL in regressing tumors of FVB/N mice treated with a GM‐CSF secreting HER‐2/neu targeted whole cell vaccine. Foxp3 expression in tumor antigen‐specific CD8 T cells is restricted to the tumor microenvironment and influenced by cues in the tumor. Interestingly, Foxp3^+^ and Foxp3^−^ CD8^+^ T cells have similar IFN‐γ production and antigen‐specific degranulation after stimulation with RNEU~420–429~, the immunodominant HER‐2/neu (neu) epitope in this model. Adoptive transfer studies, using RNEU~(420–429)~‐specific effector T cells into neu‐N mice (a model that results in immune tolerance to neu), confirm that CD8^+^Foxp3^+^ T cells are present in tumors only if there is an existing pool of tumor‐rejecting effector T cells. CD8^+^Foxp3^+^ TILs mark the presence of tumor‐rejecting antigen‐specific T cells and their accumulation serves as a marker for an effective T cell response.


📜 SIMILAR VOLUMES


B cell depletion may be more effective t
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt